Preliminary Agenda

Day 1: Thursday, May 13
Major Challenges to Development
of New Therapeutics and Diagnostics

7:30 am Registration
8:30 am Welcome FDA/NIH
– Allen Spiegel, Director NIDDK; Lester Crawford, Acting Commissioner, FDA

Session I: Overview/Setting the Stage

8:50 am The Realities of Diabetes Mellitus in 2004
– David Nathan, Harvard Medical School
9:20 am Duality of Type 2 Diabetes Mellitus
– Peter Wilson, Medical University of South Carolina
9:50 am Discussion
10:15 am BREAK

Session II: New Targets of Intervention

10:30 am Molecular Targets in Type 2 Diabetes Mellitus
– Nancy Thornberry, Merck and Company
11:00 am Immunomodulation in Type 1 Diabetes Mellitus
– George Eisenbarth, University of Colorado Health Sciences Center
11:30 am Discussion
11:55 am LUNCH (on your own)

Session III: Beta Cell Preservation

1:10 pm Type 1 Diabetes Mellitus
– Jerry Palmer, Seattle VA Puget Sound Health Care System
1:40 pm Type 2 Diabetes Mellitus
– Steven Kahn, VA Puget Sound Health Care System
2:10 pm Discussion

Session IV: Islet Transplantation

2:30 pm Islet Transplants: Past, Present, and Future
– Bernhard Hering, University of Minnesota
3:00 pm Hurdles in the Clinical Application of Islet Transplantation
– Robert Sherwin, Yale University School of Medicine
3:30 pm Discussion
4:00 pm BREAK

Session V: Devices

4:20 pm Continuous Glucose Sensors in Diabetes
– William Tamborlane, Yale University School of Medicine
4:45 pm Pumps: Hopes and Expectations
– Christopher Saudek, The Johns Hopkins Medical Institutions
5:10 pm Discussion
5:30 pm ADJOURN

back to top

Day 2: Friday, May 14
Perspectives on the Future of Prevention and Therapy

7:00 am Registration

Session VI: Prevention of Type 2 Diabetes

8:00 am Metabolic Syndrome: An Overview
– Barbara Howard, MedStar Research Institute
8:25 am Metabolic Syndrome: A Potential Target for
Prevention of Type 2 Diabetes Mellitus
– Robert Eckel, University of Colorado Health Sciences Center
8:50 am Diabetes Prevention Program: Lessons for Therapy
– Harry Shamoon, The Albert Einstein College of Medicine
9:15 am Discussion
9:35 am BREAK

Session VII: Industry and Advocacy Perspectives

9:55 am Drugs
– Simeon Taylor, Bristol-Myers Squibb Pharmaceutical Research Institute
10:10 am Biologics
10:25 am Devices
– Richard Naples, Roche Diagnostics
10:40 am American Diabetes Association
– Nathaniel Clark
10:55 am Juvenile Diabetes Research Foundation International
– Robert Goldstein
11:10 am Discussion

Session VIII: Targeting Safe and Effective Prevention
and Treatment: Steps Forward by FDA and NIH

11:35 am Panel Discussion
12:30 am Closing

back to top